OPTAVIA ASCEND was designed to fill an important gap in the market and now allows us to provide a simple solution combining high-protein products, daily nutrient packs, the personalized guidance of a coach and the support of a community
Figure 2: Changes in body weight from baseline to the end of treatment at week 26 associated with the treatment policy estimand, in the randomly assigned treatment groups administered either 0.3 mg of cagrilintide, 0.6 mg of cagrilintide, 1.2 mg of cagrilintide, 2.5 mg of cagrilintide, 4.5 mg of cagrilintide, 3.0 mg of liraglutide, or a placebo
Research by the National Institute on Drug Abuse shows that people who begin treatment soon after problematic use are more likely to complete rehabilitation programs and maintain long-term abstinence
Commercial insurers often impose step therapy, meaning patients must fail metformin or other agents before approval